Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Alogliptin renal doses and HD timing do not determine eligibility for an alogliptin/metformin fixed combination. Peritoneal dialysis remains unstudied.
Before applying: Check every component and the dialysis modality before applying the single-agent schedule.
Also check: NESINA: single-agent renal dosing is not combination eligibility
Official source
Alogliptin tablets (single agent) - selected U.S. labeling
Product / population
Adults with type 2 diabetes; oral alogliptin single-agent tablets, not alogliptin/metformin or alogliptin/pioglitazone combinations.
Renal measure
Creatinine clearance (CrCl) in mL/min, as specified in the selected U.S. labeling.
Labeled basic dosing
Renal function (CrCl, mL/min)
Oral dose
60 or higher
25 mg once daily
30 to less than 60
12.5 mg once daily
Below 30, including ESRD/hemodialysis
6.25 mg once daily
Renal information and dialysis
Check kidney function before initiation and periodically. Hemodialysis timing does not require changing administration time. Peritoneal dialysis was not studied in the label.
Selected warnings and limits
Review pancreatitis, heart-failure risk, serious hypersensitivity and hepatic injury; hypoglycemia risk rises with insulin or sulfonylureas.
Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Renal Drug Handbook, fifth edition - Alogliptin tablets (single agent)
Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods. Retrieved: 2026-09-05
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
formulation scope
NESINA: single-agent renal dosing is not combination eligibility
Alogliptin renal doses and HD timing do not determine eligibility for an alogliptin/metformin fixed combination. Peritoneal dialysis remains unstudied.
How to use this: Check every component and the dialysis modality before applying the single-agent schedule.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
Alogliptin tablets (single agent) - selected U.S. labeling
Adults with type 2 diabetes; oral alogliptin single-agent tablets, not alogliptin/metformin or alogliptin/pioglitazone combinations.
Method: Creatinine clearance (CrCl) in mL/min, as specified in the selected U.S. labeling.
Renal Drug Handbook, fifth edition - Alogliptin tablets (single agent)
Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
U.S. product labeling / DailyMed · Adults with type 2 diabetes; oral alogliptin single-agent tablets, not alogliptin/metformin or alogliptin/pioglitazone combinations.
Renal method: Creatinine clearance (CrCl) in mL/min, as specified in the selected U.S. labeling. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Check kidney function before initiation and periodically. Hemodialysis timing does not require changing administration time. Peritoneal dialysis was not studied in the label.
GlobalRPh-hosted RX List · Alogliptin - NESINA tablets; selected source sections, not a full prescribing monograph.
Renal method: Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Assess renal function before treatment and periodically. At CrCl >=60 mL/min, no adjustment is needed. At CrCl >=30 to <60, use 12.5 mg once daily. At CrCl >=15 to <30 or ESRD (<15 or hemodialysis), use 6.25 mg once daily. Dosing need not be timed to hemodialysis. Peritoneal dialysis has not been studied. This single-agent guidance is not the renal eligibility rule for an alogliptin/metformin fixed combination.
UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods. Source date: Fifth edition, 2019 Retrieved: 2026-09-05
Historical source, separately displayed. Renal tables were read with page-image inspection.
Historical renal and dialysis observations
The book gives 12.5 mg/day at 30-50 mL/min and 6.25 mg/day in its 10-30 and below-10 bands. It notes approximately 7% removal during a 3-hour hemodialysis session despite broadly describing limited dialysis removal.
RDM31-alogliptin-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information
Source-specific limits
The historical bands overlap at 30 and do not cover the label's full 30-to-less-than-60 band. Use the selected source's complete boundaries, not a hybrid table.
Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 44; PDF page(s) 63
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.